Consano Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-12.
Consano Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 12, 2025. The filing reports $16.84M sold. Its industry group is Biotechnology. It names Andrew Hall (Chief Executive Officer and Secretary of Issuer), Jennifer Schmitke (President and Chief Operating Officer of Issuer), Doug Weide (Director) (SEC Form D, December 12, 2025).
Sell to companies like Consano Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Consano Bio, Inc.
Free to see. No signup.
More on the people and the money behind Consano Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in December 2025, largest first.
Get an email when Consano Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Consano Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Consano Bio, Inc. →Get the full cited report on Consano Bio, Inc.
What the filing shows about Consano Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Consano Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Consano Bio, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $16.84M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Andrew Hall is named as Chief Executive Officer and Secretary of Issuer on the Form D that Consano Bio, Inc. filed with the SEC on 12 December 2025, one of 6 people that filing names.
On the filing as: Executive Officer.
Jennifer Schmitke is named as President and Chief Operating Officer of Issuer on the Form D that Consano Bio, Inc. filed with the SEC on 12 December 2025, one of 6 people that filing names.
Doug Weide is named as Director on the Form D that Consano Bio, Inc. filed with the SEC on 12 December 2025, one of 6 people that filing names.
Chris Centeno is named as Director on the Form D that Consano Bio, Inc. filed with the SEC on 12 December 2025, one of 6 people that filing names.
Bill Abbington is named as Director on the Form D that Consano Bio, Inc. filed with the SEC on 12 December 2025, one of 6 people that filing names.
Jerome Adams is named as Director on the Form D that Consano Bio, Inc. filed with the SEC on 12 December 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-12-12 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Consano Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Consano Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Consano Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Consano Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Consano Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Consano Bio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
https://mentionfox.com/funding/consano-bio-inc-form-d-25000001